GLPwatch
Papers (9189)
Page 117 of 154, ranked by citation count.
- Liraglutide ameliorates diabetic kidney disease by modulating gut microbiota and L-5-Oxoproline.
- Once-yearly device takes on daily and weekly diabetes drugs.
- First Reported Case of Dulaglutide-Induced Acute Pancreatitis With Normal Serum Lipase Level.
- Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells.
- Add on Exenatide Treatment is Beneficial in Poorly Controlled Obese Type 2 Diabetics under Intensive Insulin Regimens.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.
- Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China.
- The diabetic muscle.
- Comparative cardiovascular effects of GLP-1 agonists using real-world data.
- Metformin-associated lactic acidosis precipitated by liraglutide use: adverse effects of aggressive antihyperglycaemic therapy.
- Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.
- Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.
- Response to Comment on Tang et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care 2015;38:1339-1346.
- Instrumental Variable Methods to Target Hypothetical Estimands With Longitudinal Repeated Measures Data: Application to the STEP 1 Trial.
- Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.
- Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
- Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide.
- IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective.
- Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials.
- Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies.
- Relationship of vascular complications and exenatide therapy failure in type 2 diabetic patients.
- Renal effects of exendin-4 in an animal model of brain death.
- A Pharmacological Dose of Liraglutide Improves Mitochondrial Performance in Mouse Leydig Cells.
- Glucagon-Like Peptide-1 Receptor Agonists During Electroconvulsive Therapy: Case Report With Evolving Concerns and Management Considerations.
- Quantification of the effect of GLP-1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition model.
- Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.
- Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People.
- Chitosan hydrochloride coated and nonionic surfactant modified niosomes: a better way for oral administration of semaglutide.
- Exendin-4 improves resistance to Listeria monocytogenes infection in diabetic db/db mice.
- The etiopathogenesis and management of obesity: The quintessential quincunx.
- The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
- GLP-1 Receptor Agonists Are Associated with Reduced Ascending Aorta Dilatation in Patients with Type 2 Diabetes: A Prospective Study.
- Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, double-blind, placebo-controlled, investigator-initiated study.
- A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.
- Association between eating behavior patterns and the therapeutic efficacy of GLP-1 receptor agonists in individuals with type 2 diabetes: a multicenter prospective observational study.
- Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
- Exendin-4 Induces Cytotoxic Autophagy in Two Ovarian Cancer Cell Lines through Inhibition of Mtorc1 Mediated by Activation of AMPK and Suppression of Akt.
- Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
- Should family physicians prescribe medication for obesity? NO.
- Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.
- Drug-Induced Liver Injury Due to Dulaglutide Use.
- Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis.
- Effects of all-trans retinoid acid and exendin-4 on islet transplantation in NOD mice.
- Liraglutide improved glycaemic instability in a patient with diabetes with insulin antibodies.
- [Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
- Semaglutide attenuates Alzheimer's disease model progression by targeting microglial NLRP3 inflammasome-mediated neuroinflammation and ferroptosis.
- Impacts of tirzepatide on older patients with diminished β-cell function and dementia.
- The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment.
- Youth Perspectives on the Use of Medications for Weight Loss.
- Metabonomic analysis of the therapeutic effect of exendin-4 for the treatment of tBHP-induced injury in mouse glomerulus mesangial cells.
- Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.
- Elderly rats fed with a high-fat high-sucrose diet developed sex-dependent metabolic syndrome regardless of long-term metformin and liraglutide treatment.
- Liraglutide and learning.
- Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
- Activation of G-protein-coupled receptors and thyroid malignant tumors: the jury is still out.
- GLP-1R/NPY2R regulate gene expression, ovarian and adrenal morphology in HFD mice.
- An Overview of the Burden of Illness and the Role of Once-Weekly Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Type 2 Diabetes.
- Insulins for type 2 diabetes.
- Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.